Abbott’s MD&A discloses several initiatives that align with the broadening scope of IT capability through the integration and mobilization of digital resources across its operations. On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc., “which will further Abbott’s efforts to develop connected solutions for making diabetes management more personal and precise,” highlighting the firm’s focus on interconnected digital technologies and data‐driven patient care. In its diagnostics segment, Abbott has continued “to build out its test menu for clinical chemistry and immunoassay diagnostics” while expanding its IT infrastructure, receiving FDA approval in the fourth quarter of 2023 for its new laboratory automation system, GLP Systems Track™, “to help laboratories optimize the performance and safety of diagnostics testing,” and deploying “informatics solutions to help optimize diagnostics laboratory performance and automation solutions to increase efficiency in laboratories,” reflecting investments in data management, process automation, and information reliability. Within medical devices, research and development programs include neuromodulation efforts “leveraging digital health to support improved patient clinical outcomes, physician engagement, and expanded indications” and the development of “next‐generation rhythm management technologies, including advanced communication capabilities and leadless pacing therapies,” demonstrating Abbott’s commitment to advancing IT architecture, connectivity, and operational flexibility in support of its business strategies and work processes.